Does UnitedHealthcare Cover Eliquis (Apixaban)?

What Is Eliquis and Why Do Patients Need It?

Eliquis is the brand name for apixaban, a direct oral anticoagulant (DOAC) that blocks Factor Xa in the coagulation cascade. The FDA approved apixaban in December 2012 for reducing stroke risk in nonvalvular atrial fibrillation and for treating deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also approved for post-orthopedic-surgery VTE prophylaxis [1].

Clinical Evidence Behind the Approval

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against warfarin in patients with atrial fibrillation. Apixaban reduced stroke or systemic embolism by 21% (1.27% vs. 1.60% per year; P<0.001), reduced major bleeding by 31%, and cut all-cause mortality by 11% compared to warfarin [2]. These results, published in the New England Journal of Medicine in 2011, form the core of every major guideline recommendation for apixaban.

The AMPLIFY trial (N=5,395) demonstrated that apixaban was non-inferior to conventional therapy (enoxaparin/warfarin) for acute VTE treatment, with significantly less major bleeding (0.6% vs. 1.8%; P<0.001) [3].

Why Formulary Placement Matters Clinically

The 2023 ACC/AHA Atrial Fibrillation Guideline gives a Class I recommendation to DOACs over warfarin for most patients with nonvalvular AF [4]. When a patient's DOAC is placed on a high formulary tier or denied by prior authorization, the real-world consequence is delayed or abandoned therapy, which raises stroke risk directly. One analysis in the Journal of Managed Care and Specialty Pharmacy found that formulary restrictions on DOACs were associated with a 12 to 18% reduction in adherence within 90 days of prescription.

How UnitedHealthcare Formularies Work

UHC operates multiple formulary structures across its product lines. Understanding which product line applies to your plan is the first step to knowing your Eliquis cost.

Commercial (Employer-Sponsored and Individual/Family) Plans

UHC's commercial plans typically use a 5-tier formulary. Eliquis most commonly lands on:

• Tier 3 (Preferred Brand): Copays of $50, $100 per 30-day supply after the plan deductible.
• Tier 4 (Non-Preferred Brand): Copays of $80, $150 or higher, and some plans apply coinsurance (25 to 40%) rather than a flat copay.

Prior authorization is required on the majority of commercial plans. The UHC PA criteria for apixaban typically require documentation of a qualifying diagnosis (AF, DVT, PE, or post-surgical prophylaxis), a reason warfarin is not preferred (e.g., labile INR, patient refusal of monitoring, drug interaction), and in some cases a trial of warfarin. The FDA label itself does not require warfarin failure before initiating apixaban, so a step-therapy requirement of this kind can be contested [5].

Medicare Advantage Plans (Part C with Integrated Part D)

UHC is the largest Medicare Advantage insurer in the United States, covering more than 9 million Medicare Advantage enrollees as of 2024. Most UHC Medicare Advantage plans include integrated Part D drug coverage.

Eliquis sits on Tier 3 or Tier 4 of UHC's Medicare Advantage formularies. Under the Inflation Reduction Act of 2022, the maximum out-of-pocket cap for Part D drugs dropped to $2,000 in 2025, which meaningfully reduces catastrophic exposure for patients on Eliquis year-round [6].

During the coverage gap phase (prior to hitting the catastrophic threshold), cost-sharing on a Tier 3 or Tier 4 drug varies by plan. UHC's AARP MedicareRx plans, which are standalone Part D plans, often place apixaban at 25 to 33% coinsurance in the coverage gap.

UnitedHealthcare Medicaid (Community Plan)

Medicaid formularies are state-administered, and UHC's Medicaid managed care plans (marketed as UnitedHealthcare Community Plan) follow each state's preferred drug list (PDL). Some states, including Texas and Florida, include apixaban on their PDL; others list it as a non-preferred agent requiring prior authorization. Patients on UHC Medicaid should contact their state plan directly or use the plan's online drug search tool.

Prior Authorization for Eliquis Under UHC

Prior authorization (PA) is the single largest barrier to timely Eliquis access under UHC coverage. Most plans impose it.

Typical PA Criteria

UHC's medical necessity criteria for apixaban PA generally require:

1. A documented diagnosis from the FDA-approved indication list (nonvalvular AF, DVT, PE, post-joint-replacement prophylaxis).
2. A physician attestation or clinical notes supporting anticoagulation therapy.
3. On some plans, documentation that the patient has contraindications to warfarin or that warfarin monitoring is not feasible.

Step therapy (mandatory warfarin trial first) is the most contested component. The American College of Cardiology's position statement on step therapy notes that requiring a warfarin trial before a DOAC is inconsistent with current evidence-based guidelines for most AF patients [4].

How to File a PA Request

Your prescribing physician or their office staff submits the PA through UHC's Provider Portal or by fax using UHC's standard PA form. The standard turnaround is 3 business days for non-urgent requests and 1 business day for urgent/expedited requests under CMS rules.

If the PA is denied, you have the right to appeal. The first level is an internal appeal with UHC, which must be resolved within 30 days (non-urgent) or 72 hours (expedited). If that fails, you can request an independent external review through your state insurance commissioner's office.

Step Therapy Override Laws

As of 2024, 33 states have enacted step therapy override laws that require insurers to approve a step therapy exception when a prescriber documents that the required first-step drug is contraindicated, has failed, or is not in the patient's best clinical interest [7]. If you live in one of those states and your UHC commercial plan denies Eliquis pending a warfarin trial, your physician can file a step therapy exception request citing clinical necessity.

What Eliquis Actually Costs Under UHC

Cost-sharing depends on plan type, deductible status, and whether you have met your out-of-pocket maximum.

Commercial Plan Cost Examples

| Scenario | Estimated Monthly Cost | |---|---| | Tier 3, deductible met, $75 copay | $75 | | Tier 4, deductible not met, 30% coinsurance | $165, $195 | | Tier 4, deductible met, 30% coinsurance | $165, $195 | | Out-of-pocket maximum reached | $0 |

These figures assume a standard retail cost of $550, $650 per 30-day supply for apixaban 5 mg twice daily. Prices vary by pharmacy.

Medicare Part D Cost Examples

Under the 2025 Part D redesign mandated by the Inflation Reduction Act:

• Deductible phase: Patients pay 100% up to the $590 deductible (2025 standard).
• Initial coverage phase: 25% coinsurance until total drug costs reach $2,000 out-of-pocket.
• Catastrophic phase: $0 cost-sharing after $2,000 out-of-pocket maximum [6].

A patient on Eliquis 5 mg twice daily paying $580/month retail would hit the $2,000 out-of-pocket cap by approximately April under a standard Part D plan, after which all Eliquis fills are free for the rest of the calendar year.

How to Reduce Your Out-of-Pocket Cost for Eliquis

Several programs exist to lower costs, even if UHC's formulary tier is unfavorable.

Bristol-Myers Squibb / Pfizer Copay Card

For commercially insured patients (not Medicare or Medicaid), the Eliquis manufacturer copay card reduces cost-sharing to as low as $10 per month. Eligibility requires commercial insurance and income qualification in some cases. The program does not apply to government-funded plans, including Medicare Part D [8].

Patient Assistance Programs

Bristol-Myers Squibb's Together on Diabetes/Eliquis 360 patient assistance program provides free Eliquis to uninsured or underinsured patients who meet income criteria (generally household income at or below 400% of the federal poverty level). The application is submitted by the prescriber on behalf of the patient.

Pharmacy Switching

Some UHC plans have preferred pharmacy networks. Using a preferred pharmacy (CVS, Walgreens, or UHC's own OptumRx mail-order pharmacy) can reduce tier cost-sharing by one tier level in certain plan designs. For Medicare Part D patients, mail-order fills of a 90-day supply often carry lower per-unit copays than 30-day retail fills.

Therapeutic Alternatives

If PA is denied and appeals fail, the prescribing physician may consider other Factor Xa inhibitors. Rivaroxaban (Xarelto) and edoxaban (Savaysa) carry similar clinical profiles for AF stroke prevention and VTE treatment. In the ROCKET AF trial (N=14,264), rivaroxaban 20 mg daily was non-inferior to warfarin for AF stroke prevention (1.7% vs. 2.2% per year; P<0.001 for non-inferiority) [9]. Some UHC formularies place rivaroxaban on a lower tier than apixaban, which may reduce cost-sharing for patients who are clinically appropriate candidates.

The choice between DOACs should remain a clinical decision between physician and patient. Apixaban demonstrated lower major bleeding rates than rivaroxaban in a large network meta-analysis (odds ratio 0.77; 95% CI 0.64 to 0.93) [10], so formulary-driven switching should be reviewed carefully with a cardiologist or hematologist.

Appealing a UHC Denial for Eliquis

A denial is not the end of the road. The appeals process is structured and has defined timelines.

Internal Appeal

Submit a written appeal within 180 days of the denial notice. Include:

• The original denial letter.
• A letter of medical necessity from the prescriber citing the relevant trial data (ARISTOTLE for AF, AMPLIFY for VTE).
• Office visit notes documenting the diagnosis and treatment rationale.
• Any documentation of warfarin intolerance, labile INR history, or monitoring difficulty.

UHC must respond within 30 calendar days for standard pharmacy appeals and 72 hours for expedited requests where a delay could seriously jeopardize health.

External Review

If the internal appeal is denied, federal law (under the ACA) guarantees the right to an independent external review for non-grandfathered plans [11]. Request this through UHC's denial letter instructions or directly through your state insurance department. External reviewers are IRO (independent review organization) panels that are not affiliated with UHC. Reversal rates at external review for medically necessary branded drugs range from 40 to 60% in published state insurance department data.

Filing a Complaint

The Centers for Medicare and Medicaid Services (CMS) oversees Medicare Advantage and Part D plans. Beneficiaries can file a complaint directly with CMS at 1-800-MEDICARE or through Medicare.gov if UHC violates required timelines or formulary transparency rules [12].

Eliquis Dosing Reference for Prescribers and Patients

The FDA-approved dosing schedule for apixaban depends on indication [1]:

Nonvalvular Atrial Fibrillation

Standard dose: 5 mg orally twice daily. Dose reduction to 2.5 mg twice daily applies when at least two of the following are present: age 80 or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher.

DVT and PE Treatment

10 mg twice daily for 7 days, then 5 mg twice daily. For extended prevention of recurrent VTE after at least 6 months of treatment: 2.5 mg twice daily.

Post-Orthopedic Surgery Prophylaxis

2.5 mg twice daily starting 12 to 24 hours post-surgery. Duration: 12 days after knee replacement, 35 days after hip replacement.

Renal impairment: No dose adjustment required for mild-to-moderate renal impairment when used for AF. For VTE treatment, use with caution in severe renal impairment (CrCl <15 mL/min); apixaban has not been studied in dialysis patients for this indication [1].

Special Populations and Coverage Considerations

Elderly Patients on Medicare

Patients 65 and older account for the largest share of apixaban prescriptions, given AF prevalence rises to roughly 9% in adults over 65 [13]. The 2025 Part D $2,000 out-of-pocket cap is especially significant for this group. CMS data show that before the IRA reforms, nearly 1.4 million Part D enrollees reached catastrophic coverage thresholds annually, with anticoagulants among the most common drug classes driving that exposure.

Patients with Renal Disease

Chronic kidney disease (CKD) affects approximately 15% of U.S. Adults, and anticoagulation decisions in CKD require careful dose assessment [14]. Apixaban is generally preferred over warfarin in moderate CKD (stages 3 to 4) for AF, based on pharmacokinetic data showing that only 27% of apixaban is renally cleared. UHC PA criteria do not typically require different documentation for CKD patients, but prescribers should note the dose-reduction criteria in PA submissions.

Pregnancy

Apixaban carries an FDA category warning against use in pregnancy due to bleeding risk and potential fetal harm. Low-molecular-weight heparin (LMWH) remains the anticoagulant of choice in pregnancy per ACOG guidelines [15]. UHC formularies typically do not cover apixaban for pregnancy-related indications.

HealthRX Clinical Decision Framework: Navigating UHC Coverage for Eliquis

The following stepwise approach is designed for prescribers and patients working through UHC coverage barriers. It consolidates the coverage rules, appeal rights, and clinical alternatives into a practical sequence.

Step 1: Confirm plan formulary status. Use UHC's online drug formulary search tool (available at myuhc.com or uhcprovider.com) to identify the exact tier and PA requirements for your specific plan year.

Step 2: Submit PA with complete clinical documentation upfront. Include the diagnosis, relevant trial citations (ARISTOTLE [2] for AF; AMPLIFY [3] for VTE), contraindications to warfarin if applicable, and CrCl/renal function data.

Step 3: If PA is denied, file an internal appeal within 180 days. Attach a physician letter citing the ACC/AHA Class I DOAC recommendation [4] and any step therapy override law applicable in your state [7].

Step 4: If internal appeal fails, request independent external review. Federal ACA rights apply to most non-grandfathered commercial plans [11]. CMS complaint filing applies to Medicare Advantage and Part D plans [12].

Step 5: Explore cost-reduction programs in parallel. Apply for the BMS/Pfizer copay card (commercial plans) or the Together patient assistance program (uninsured/underinsured). Consider OptumRx mail-order for 90-day supply savings.

Step 6: If coverage cannot be secured, review therapeutic alternatives with the treating cardiologist. Clinical suitability for rivaroxaban, edoxaban, or dabigatran should be assessed individually, with attention to bleeding risk profiles and renal function.